Kineret (anakinra) – Rheumatoid Arthritis (RA) Therapy in India
Kineret (anakinra) is indicated for treating moderately to severely active Rheumatoid Arthritis (RA) in adults failing other DMARDs, and for rare autoinflammatory conditions like Cryopyrin-Associated Periodic Syndromes (CAPS), including NOMID, and Deficiency of Interleukin-1 Receptor Antagonist (DIRA), plus Still’s Disease (SJIA/AOSD) in specific age groups, working by blocking inflammation-causing interleukin-1. It’s an immunosuppressant that blocks immune chemical messengers.
| Brand Name: | Kineret |
| Generic Name: | anakinra |
| Strength: | Injection: 100 mg/0.67 mL solution in a single-use prefilled syringe for subcutaneous injection. Graduated syringe allows for doses between 20 mg and 100 mg. |
| Manufacturer: | Swedish Orphan Biovitrum AB (publ) |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
Kineret must always be used under the supervision of a Registered Medical Practitioner (RMP).
Get access to Kineret in India for treatment of Rheumatoid Arthritis (RA) on a Named Patient Import Basis.
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Kineret (anakinra) for injection for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding imported medicine pricing estimates in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.
